The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Nasal polyps are benign (non-cancerous) growths that develop inside the nose or sinuses. Common causes of nasal polyps include asthma, allergies, and chronic sinus infections. Nasal polyps are ...

What you may think are allergies or a cold, could be the sign of nasal polyps. Nasal polyps are non-cancerous growths that line the nasal passages and sinuses. They are soft, painless, and hang ...

Opens in a new tab or window The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

These quiz questions about nasal polyps (NP) are derived from recent literature. Are you up to date? At the end of the quiz, compare your score with those of your physician colleagues. Links to ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

GSK receives Japanese MHLW approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Thursday, August 29, 2024, 09:00 Hrs [IST] GSK plc announc ...

(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adolescent patients aged ...

“We are pleased to bring the well-established efficacy and safety of Dupixent to the many children suffering from chronic rhinosinusitis with nasal polyps, which can make their breathing more ...

During a nasal endoscopy, the health care provider tries to look inside your nose or the opening of the sinus passage to ...